Patents Assigned to Nanjing Zhengxiang Pharmaceuticals Co., Ltd.
  • Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors
    Patent number: 11673889
    Abstract: The invention provides compounds of Formula (A) that may inhibit ENPP1, and that are accordingly useful for treatment of disorders related to ENPP1. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent disorders related to ENPP1.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: June 13, 2023
    Assignee: NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.
    Inventor: Xiaolin Hao
  • Phosphatidylinositol 3-kinase inhibitors
    Patent number: 11542262
    Abstract: The present disclosure provides selective phosphoinositide 3-kinase gamma inhibitors of Formula (I) including (I-a), (I-b), (I-c), and (I-d), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated by one or more PI3K isoforms, such as PI3K gamma (PI3K?). The present disclosure further provides methods of inhibiting phosphoinositide 3-kinase gamma using these compounds for treatment of disorders related to phosphatidylinositol 3-kinase gamma activity.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: January 3, 2023
    Assignee: NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.
    Inventor: Xiaolin Hao
  • Compounds useful to treat influenza virus infections
    Patent number: 11466029
    Abstract: The invention provides compounds that may inhibit influenza virus replication, and are accordingly useful for treatment of viral infections caused by influenza virus. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent viral infections caused by influenza virus.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: October 11, 2022
    Assignee: NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.
    Inventors: Xiaolin Hao, Jinfu Yang
  • Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
    Patent number: 11446301
    Abstract: The present disclosure provides selective phosphoinositide 3-kinase inhibitors of formula (A), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated by one or more P13K isoforms, such as PI3K delta (PI3K?). The present disclosure further provides methods of inhibiting phosphoinositide 3-kinase inhibitors using these compounds for treatment of disorders related to phosphatidylinositol 3-kinase activity.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: September 20, 2022
    Assignee: NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.
    Inventor: Xiaolin Hao
  • COMPOUNDS USEFUL TO TREAT INFLUENZA VIRUS INFECTIONS
    Publication number: 20220033416
    Abstract: The invention provides compounds that may inhibit influenza virus replication, and are accordingly useful for treatment of viral infections caused by influenza virus. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent viral infections caused by influenza virus.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 3, 2022
    Applicant: Nanjing Zhengxiang Pharmaceuticals Co., Ltd.
    Inventors: Xiaolin HAO, Jinfu YANG